CN110412274A - C6ORF106 autoantibody detection reagent is preparing the purposes in screening lung cancer kit - Google Patents
C6ORF106 autoantibody detection reagent is preparing the purposes in screening lung cancer kit Download PDFInfo
- Publication number
- CN110412274A CN110412274A CN201910562564.7A CN201910562564A CN110412274A CN 110412274 A CN110412274 A CN 110412274A CN 201910562564 A CN201910562564 A CN 201910562564A CN 110412274 A CN110412274 A CN 110412274A
- Authority
- CN
- China
- Prior art keywords
- reagent
- c6orf106
- lung cancer
- autoantibody
- detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to external diagnosis reagent fields, and in particular to C6ORF106 autoantibody detection reagent is preparing the purposes in screening lung cancer kit.Present invention firstly discovers that the autoantibody of C6ORF106 albumen is significantly higher than healthy patients in Serum of Patients with Lung Cancer.The reagent that the present invention will test C6ORF106 albumen autoantibody is used to prepare screening lung cancer kit, can be realized effective screening of lung cancer.
Description
Technical field
The present invention relates to external diagnosis reagent fields, and in particular to C6ORF106 autoantibody detection reagent is in preparation lung cancer
Purposes in kit for screening.
Background technique
Lung cancer is that one of most common malignant tumour, morbidity and mortality are in rise year by year trend in the world, at present
Disease incidence occupies first place in the world, and seriously threatens human health and life.
Lung cancer is a kind of disease for being good at concealment, often develops to advanced stage in disease and just shows clinical symptoms, 70~
80% patients with lung cancer has been middle and advanced stage when being diagnosed to be with Lung Cancer Symptoms, and cancer cell has been spread, and misses best healing
Opportunity, five year survival rate are low.For the patients with lung cancer of early stage, giving birth to for 5 years or more for patient is greatly improved by treating in time
Deposit rate and life quality.Therefore the early diagnosis and the effective screening of progress of lung cancer are most important.
The screening of lung cancer, referring to does not have the related indication crowd of lung cancer to carry out routine physical examination those, before there is symptom
Discovery lung cancer in time.If the lung cancer molecular marker inside blood plasma can be found, for prompting clinician's early stage to patient
Relevant remedy measures or decision are taken to have great importance.
Autoantibody refers to the antibody that body generates itself organ, cell or cell component.Currently, certain albumen from
Body antibody has become the marker of lung cancer, such as: p53, NY-ESO-1, CYFRA (Tang Z-M, Ling Z-G, Wang
C-M,Wu Y-B,Kong J-L(2017)Serum tumor-associated autoantibodies as diagnostic
biomarkers for lung cancer:Asystematic review and meta-analysis.PLoS ONE 12
(7):e0182117)。
C6ORF106 (Ensembl:ENSG00000196821) also known as ILRUN is generally deposited in the tissue such as testis, fat
It is expressing.The relevant report of C6ORF106 albumen autoantibody is had not yet to see, also has no its prior art relevant to lung cancer.
Summary of the invention
The purpose of the present invention is to provide the detections of the lung cancer marker and the marker of a kind of new autoantibody class
Reagent is preparing the purposes in screening lung cancer kit.
Technical solution of the present invention includes:
The reagent of detection C6ORF106 albumen autoantibody is preparing the purposes in screening lung cancer kit.
Purposes as the aforementioned, the reagent of the detection C6ORF106 albumen autoantibody are enzyme-linked immunosorbent assay examination
Agent or linked immune analysis reagent.
The reagent of purposes as the aforementioned, the detection C6ORF106 albumen autoantibody is western blot reagent.
Purposes as the aforementioned, the reagent of the detection C6ORF106 albumen autoantibody are the examination of protein chip detection method
Agent.
Purposes as the aforementioned, the reagent of the detection C6ORF106 albumen autoantibody are C6ORF106 in detection human serum
The reagent of albumen autoantibody.
A kind of screening lung cancer kit, it includes the reagent for detecting C6ORF106 albumen autoantibody.
Kit as the aforementioned, the reagent of the detection C6ORF106 albumen autoantibody are enzyme-linked immunosorbent assay use
Reagent or ELISA reagent.
The reagent of kit as the aforementioned, the detection C6ORF106 albumen autoantibody is western blot reagent.
Kit as the aforementioned, the reagent of the detection C6ORF106 albumen autoantibody are protein chip detection method use
Reagent.
Kit as the aforementioned, the reagent of the detection C6ORF106 albumen autoantibody are in detection human serum
The reagent of C6ORF106 albumen autoantibody.
The present invention provides a kind of new screening lung cancer markers and a kind of new screening lung cancer kit, can be realized lung
Effective screening of cancer；And patient can be injured very low using serum as test sample.The present invention has good application prospect.
Obviously, above content according to the present invention is not being departed from according to the ordinary technical knowledge and customary means of this field
Under the premise of the above-mentioned basic fundamental thought of the present invention, the modification, replacement or change of other diversified forms can also be made.
Above content of the invention is described in further detail again below by way of specific embodiment.But it should not be by this
The range for being interpreted as the above-mentioned theme of the present invention is only limitted to example below.All technologies realized based on above content of the present invention are equal
Belong to the scope of the present invention.
" C6ORF106 autoantibody " herein refers to " C6ORF106 albumen autoantibody ".
Detailed description of the invention
Fig. 1: C6ORF106 autoantibody comparison in patients with lung cancer (LC), normal healthy controls (NC) serum slurry.
Fig. 2: patients with lung cancer (LC) and normal healthy controls (NC) ROC are analyzed.
Specific embodiment
The relationship of C6ORF106 autoantibody and lung cancer in 1 blood plasma of embodiment
One, clinical data
Patients with lung cancer 30 are chosen, normal healthy controls 30, essential information is as follows:
| Essential information | Patients with lung cancer | Normal healthy controls |
| Number | 30 | 30 |
| Age | 58±10.5 | 42±8.9 |
| Masculinity proportion | 20 (66.7%) | 13 (46.7%) |
Two, testing principle
HuProtTMC6ORF106 albumen is fixed on human protein's custom chip, after increase serum is incubated for, in serum
C6ORF106 autoantibody (including mainly IgG, IgM type antibody, there are also other types of antibody) can be cleaned in conjunction with up
Removal unbonded antibody and other oroteins, then with anti-human IgM fluorescent marker secondary antibody (cy5 label, red is presented) and anti-human
IgG fluorescence secondary antibody (cy3 label, green is presented) detection, reads signal, the power of signal and the parent of antibody by Fluorescence Scanner
It is positively correlated with power and quantity.
Three, method
Reagent used in this part is as follows:
Specific step is as follows:
1) rewarming: chip is taken out from -80 DEG C of refrigerators, 4 DEG C of refrigerator rewarming half an hour is placed in, is subsequently placed in room temperature rewarming
15min；
2) close: the chip after rewarming fixes 14 blocks fences, and after fixing, envelope is added into each block
Liquid is closed, and is placed on side-sway shaking table, room temperature closes 3hr；
3) serum sample is incubated for: after the completion of closing, then confining liquid to the greatest extent is rapidly added preprepared serum and is incubated for
Liquid, every chip can be incubated for 14 serum samples, and the loading volume of each serum sample is 200 μ L, side-sway shaking table 20rpm, and 4 DEG C
It is incubated overnight (serum sample is firstly placed on 4 DEG C of chromatography cabinet freeze thawing, adds Incubating Solution with 1:50 dilution proportion, obtains serum Incubating Solution)；
4) it cleans: chip and chip fence being taken out together, suck sample, is then rapidly added isometric PBST, such as
This circulation for several times, guarantees when removing chip fence no cross contamination between serum sample.After removing chip fence, chip is placed in
Added with the chip cleaning box of cleaning solution, horizontal shaker, room temperature 80rpm is cleaned 3 times, each 10min；
5) secondary antibody is incubated for: chip being transferred in the incubation box that joined 3mL secondary antibody Incubating Solution, side-sway shaking table 40rpm is kept away
Light, room temperature 1hr；
6) it cleans: chip being taken out into (upper surface for paying attention to touch or scratching chip), is placed in the core added with cleaning solution
Piece cleaning box, horizontal shaker, room temperature 80rpm are cleaned 3 times, each 10min.It is cleaned 2 times with ddH2O after the completion, each 10min；
7) dry；
8) it scans: being scanned using brilliant core LuxScan 10K micro-array chip scanner；
9) data are extracted: corresponding GAL file (having recorded albumen position in chip) is opened, by chip image and
The each array of GAL file is integrally aligned, and presses automatic aligning button, is extracted data and is saved.
Four, result
The Average expression level of C6ORF106 autoantibody in Plasma of The Patients With Lung Cancer is that (fluorescence signal is opposite by 91.3SNR
Quantitative ratio), the Average expression level of C6ORF106 autoantibody is 52.8SNR in normal healthy controls blood plasma.Lung cancer group and health
Control group (p < 0.05) compares statistically significant (Fig. 1).The ROC of lung cancer group and normal healthy controls analyzes result specificity
96.6%, sensibility is 27.6% (Fig. 2), shows that C6ORF106 autoantibody can specifically distinguish lung cancer and normal healthy controls.
It can be seen from the above result that the level difference of patients with lung cancer and C6ORF106 autoantibody in the serum of non-lung cancer patient
Significantly, by the level of C6ORF106 autoantibody in detection serum, it can achieve the purpose that screening lung cancer.
The composition and its application method of the detection kit of the invention of embodiment 2
One, kit forms
Detection kit (14 person-portion):
Two, kit application method
With 1 Part III of embodiment --- " detection of C6ORF106 autoantibody in serum ".
Kit of the invention can be by the level of C6ORF106 autoantibody in detection serum, can be with screening people to be checked
Group suffers from the risk of lung cancer: if C6ORF106 autoantibody is high (for Healthy People), the risk for suffering from lung cancer is high, if
C6ORF106 autoantibody is low, then the risk for suffering from lung cancer is low.It can be used for the auxiliary diagnosis of clinical lung cancer, take phase for patient
The remedy measures or decision of pass provide effective foundation, and potential applicability in clinical practice is good.
Claims (10)
1. the reagent of detection C6ORF106 albumen autoantibody is preparing the purposes in screening lung cancer kit.
2. purposes as described in claim 1, which is characterized in that the reagent of the detection C6ORF106 albumen autoantibody is enzyme
Linked immunosorbent adsorption test reagent or linked immune analysis reagent.
3. purposes as described in claim 1, which is characterized in that it is described detection C6ORF106 albumen autoantibody reagent be
Western blot reagent.
4. purposes as described in claim 1, which is characterized in that the reagent of the detection C6ORF106 albumen autoantibody is egg
White chip detecting method reagent.
5. the purposes as described in Claims 1 to 4 is any, which is characterized in that the detection C6ORF106 albumen autoantibody
Reagent is the reagent for detecting C6ORF106 albumen autoantibody in human serum.
6. a kind of screening lung cancer kit, which is characterized in that it includes the reagent for detecting C6ORF106 albumen autoantibody.
7. kit as claimed in claim 6, which is characterized in that it is described detection C6ORF106 albumen autoantibody reagent be
Enzyme-linked immunosorbent assay reagent or ELISA reagent.
8. kit as claimed in claim 6, which is characterized in that it is described detection C6ORF106 albumen autoantibody reagent be
Western blot reagent.
9. kit as claimed in claim 6, which is characterized in that it is described detection C6ORF106 albumen autoantibody reagent be
Protein chip detection method reagent.
10. the kit as described in claim 6~9 is any, which is characterized in that the detection C6ORF106 albumen autoantibody
Reagent be detect human serum in C6ORF106 albumen autoantibody reagent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910562564.7A CN110412274B (en) | 2019-06-26 | 2019-06-26 | Application of C6ORF106 autoantibody detection reagent in preparation of lung cancer screening kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910562564.7A CN110412274B (en) | 2019-06-26 | 2019-06-26 | Application of C6ORF106 autoantibody detection reagent in preparation of lung cancer screening kit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110412274A true CN110412274A (en) | 2019-11-05 |
| CN110412274B CN110412274B (en) | 2022-09-09 |
Family
ID=68358301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910562564.7A Active CN110412274B (en) | 2019-06-26 | 2019-06-26 | Application of C6ORF106 autoantibody detection reagent in preparation of lung cancer screening kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110412274B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110873799A (en) * | 2019-12-09 | 2020-03-10 | 四川大学华西医院 | Application of PSMB4 autoantibody detection reagent in preparation of lung cancer screening kit |
| CN112415199A (en) * | 2020-11-20 | 2021-02-26 | 四川大学华西医院 | Application of CETP detection reagent in preparation of lung cancer screening kit |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070023448A (en) * | 2005-08-24 | 2007-02-28 | 광주과학기술원 | Autoantibody of peroxiredoxin-I as a biomarker and diagnosis kit for lung cancer using the same |
| CN101625360A (en) * | 2009-03-06 | 2010-01-13 | 中国人民解放军第二军医大学 | Kit for testing early lung cancer specific autoantibody enzyme linked immunity and preparation method thereof |
| US20150072890A1 (en) * | 2013-09-11 | 2015-03-12 | 20/20 Gene Systems, Inc. | Methods and compositions for aiding in the detection of lung cancer |
| CN105037534A (en) * | 2015-08-17 | 2015-11-11 | 吉林省吉诺生物工程有限责任公司 | Amino acid sequence for detecting lung cancer marker MYC epitope and application |
| CN106680503A (en) * | 2017-01-10 | 2017-05-17 | 河南省医药科学研究院 | Method for screening and identifying ECH1 autoantibody and application thereof |
| CN107643405A (en) * | 2017-09-19 | 2018-01-30 | 上海市肺科医院 | A kind of pulmonary cancer diagnosis kit for detecting the blood autoantibodies such as anti-TSC22D3 and detection method and its application |
| CN108646032A (en) * | 2018-06-07 | 2018-10-12 | 郑州大学 | Purposes of the TOP2A autoantibodies as pulmonary cancer diagnosis marker |
| CN109142730A (en) * | 2018-06-14 | 2019-01-04 | 郑州大学第附属医院 | A kind of anti-PSIP1 autoantibody of lung cancer marker and its application |
-
2019
- 2019-06-26 CN CN201910562564.7A patent/CN110412274B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070023448A (en) * | 2005-08-24 | 2007-02-28 | 광주과학기술원 | Autoantibody of peroxiredoxin-I as a biomarker and diagnosis kit for lung cancer using the same |
| CN101625360A (en) * | 2009-03-06 | 2010-01-13 | 中国人民解放军第二军医大学 | Kit for testing early lung cancer specific autoantibody enzyme linked immunity and preparation method thereof |
| US20150072890A1 (en) * | 2013-09-11 | 2015-03-12 | 20/20 Gene Systems, Inc. | Methods and compositions for aiding in the detection of lung cancer |
| CN105037534A (en) * | 2015-08-17 | 2015-11-11 | 吉林省吉诺生物工程有限责任公司 | Amino acid sequence for detecting lung cancer marker MYC epitope and application |
| CN106680503A (en) * | 2017-01-10 | 2017-05-17 | 河南省医药科学研究院 | Method for screening and identifying ECH1 autoantibody and application thereof |
| CN107643405A (en) * | 2017-09-19 | 2018-01-30 | 上海市肺科医院 | A kind of pulmonary cancer diagnosis kit for detecting the blood autoantibodies such as anti-TSC22D3 and detection method and its application |
| CN108646032A (en) * | 2018-06-07 | 2018-10-12 | 郑州大学 | Purposes of the TOP2A autoantibodies as pulmonary cancer diagnosis marker |
| CN109142730A (en) * | 2018-06-14 | 2019-01-04 | 郑州大学第附属医院 | A kind of anti-PSIP1 autoantibody of lung cancer marker and its application |
Non-Patent Citations (10)
| Title |
|---|
| CDI-LAB.COM: "HuProt v3 block 1", 《HTTPS://COLLECTION.CDI-LAB.COM/PUBLIC/GAL/3/1?PAGE=25》 * |
| XIN LI, ET AL.: "C6orf106 accelerates pancreatic cancer cell invasion and proliferation via activating ERK signaling pathway", 《MOLECULAR AND CELLULAR BIOCHEMISTRY》 * |
| 刘苗苗等: "七项血清自身抗体联合检测在肺癌诊断中的价值", 《中华肺部疾病杂志(电子版)》 * |
| 姜贵洋等: "C6orf106促进肺癌细胞的侵袭和增殖", 《解剖科学进展》 * |
| 姜贵洋等: "非小细胞肺癌中C6orf106的表达及意义", 《解剖学研究》 * |
| 时广利等: "非小细胞肺癌患者肺癌自身抗体检测的临床意义", 《临床肺科杂志》 * |
| 李阳等: "肿瘤自身抗体标志物的研究进展", 《生物产业技术》 * |
| 王宇璐等: "血清七种自身抗体联合癌胚抗原和糖类抗原199检测对肺癌的诊断价值", 《临床误诊误治》 * |
| 赵娟等: "7种肿瘤相关抗原自身抗体检测在肺癌诊断中的意义", 《临床检验杂志》 * |
| 邓蕾等: "人类全基因组编码蛋白质芯片技术筛选胆道闭锁自身免疫靶抗原", 《临床检验杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110873799A (en) * | 2019-12-09 | 2020-03-10 | 四川大学华西医院 | Application of PSMB4 autoantibody detection reagent in preparation of lung cancer screening kit |
| CN112415199A (en) * | 2020-11-20 | 2021-02-26 | 四川大学华西医院 | Application of CETP detection reagent in preparation of lung cancer screening kit |
| CN112415199B (en) * | 2020-11-20 | 2023-09-08 | 四川大学华西医院 | Application of CETP detection reagent in preparation of lung cancer screening kit |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110412274B (en) | 2022-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110108879A (en) | ERP27 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110108877A (en) | FAM172A autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110412274A (en) | C6ORF106 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110412276A (en) | PDE9A autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110456064A (en) | SARS2 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110108880A (en) | FEZ1 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110456083A (en) | PRKCZ autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110412281A (en) | BEGAIN autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110456067A (en) | EHD2 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110412279A (en) | KLC3 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110456061A (en) | RUNDC3A autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110412270A (en) | SSNA1 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110412298A (en) | FCRL4 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110412273A (en) | CAAP1 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110412299A (en) | HECTD3 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110456080A (en) | C14orf37 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110456065A (en) | CCDC130 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110456060A (en) | EFCAB13 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110456068A (en) | XIRP1 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110456082A (en) | PDE4DIP autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110456070A (en) | HACE1 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110108878A (en) | EIF2S1 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110488019A (en) | REPS1 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110412272A (en) | ALKBH3 autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110412275A (en) | SH3GLB2 autoantibody detection reagent is preparing the purposes in screening lung cancer kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |